Clinical Trials Logo
  1. Home
  2. Follicular Lymphoma
  3. NCT03525665
  4. Details
NCT03525665 Clinical Trial

Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression

Follicular Lymphoma Clinical Trial

Official title:
Study on the Role of FDG-PET in Patients With Follicular Lymphoma at Time of Relapse/Progression

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03525665
Other study ID # FIL_PETRA
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 2016
Est. completion date December 30, 2019

Study information
Verified date February 2020
Source Fondazione Italiana Linfomi ONLUS
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.

Description:

The study does not require any intervention on the patient, but it involves the simple collection of data that are already present in the medical record. Since this is a retrospective study, it will not require further analysis or diagnostic investigations than those already made.

Recruitment information / eligibility
Status Completed
Enrollment 175
Est. completion date December 30, 2019
Est. primary completion date December 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with initial diagnosis of follicular lymphoma since 2001

- Histological confirmation of follicular lymphoma, grade I, II, III according to WHO 2008 classification, at the time of initial diagnosis

- Systemic first-line treatment with immuno-chemotherapy

- PET availability at the time of response after first-line treatment (optional)

- Clinical and radiological evidence of FL relapse or progression

- Histological confirmation of relapse (strongly recommended)

- PET availability of at the time of relapse/progression and images available for central assessment

- Availability of clinical, laboratory and therapeutic treatment data at the time of initial diagnosis and relapse/progression

- Follow up of at least 12 months after relapse/progression

Exclusion Criteria:

- None

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Metabolic activity measured by FDG-PET
To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome.

Locations
Country Name City State
Italy SOS Ematologia Ospedale C. Massaia Asti
Italy A.O. Spedali Civili di Brescia - Ematologia Brescia
Italy Arnas Nuovo Ospedale Garibaldi Nesima - U.O.C. Ematologia Catania
Italy Az. Ospedaliero Universitaria Careggi Firenze
Italy Divisione di Ematologia Ospedale Vito Fazzi Lecce
Italy AO Ospedale Civile di Legnano Legnano
Italy Ematologia Ospedale Madonna delle Grazie Matera
Italy Ospedale Ca` Granda-Niguarda Milano
Italy Policlinico di Modena - Università degli studi Modena
Italy Azienda Ospedaliera S. Gerardo Di Monza Monza Monza Brianza
Italy AOU Maggiore della Carità di Novara - SCDU Ematologia Novara
Italy AOU Padova Padova
Italy Azienda Ospedaliera V.Cervello Palermo
Italy U.O. Ematologia e Centro Trapianto Midollo Osseo - Ospedale G. da Saliceto Piacenza
Italy A.O.R. "San Carlo" - U.O. Ematologia Potenza
Italy AO Bianchi Melacrino Morelli UO Ematologia Reggio Calabria
Italy AO Arcispedale S.Maria Nuova Ematologia Reggio Emilia
Italy CROB Rionero in Vulture Potenza
Italy Policlinico Universitario Campus Bio-Medico - "Area Ematologia Trapianto Cellule Staminali Medicina Trasfusionale e Terapia cellulare" Roma
Italy Università Cattolica del Sacro Cuore - Policlinico "A. Gemelli" Roma RM
Italy Asl Ta Di Taranto Taranto
Italy Azienda Ospedaliera "S. Maria" Terni
Italy Emat Univ - Città della salute e della scienza di Torino Torino TO
Italy U.O.C. Ematologia Ospedale "San Nicola Pellegrino" ASL BAT Trani BT
Italy A.O. C. Panico Tricase
Italy A.O. Universitaria S. Maria Della Misericordia Di Udine Udine
Italy Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI Varese

Sponsors (1)
Lead Sponsor Collaborator
Fondazione Italiana Linfomi ONLUS

Country where clinical trial is conducted

Italy, 

Outcome
Type Measure Description Time frame Safety issue
Primary PFS Progression free survival from time of relapse/progression 24 months
Secondary OS Overall survival 24 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Active, not recruiting NCT03245021 - Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A Phase 1
Active, not recruiting NCT03078855 - A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Phase 3
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT02213263 - A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) Phase 3
Completed NCT01691898 - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Terminated NCT00772668 - Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL N/A
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Terminated NCT02204982 - Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma Phase 3
Terminated NCT00850499 - Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab Phase 2
Completed NCT02536664 - Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
Terminated NCT00475332 - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar Phase 2
Terminated NCT00136591 - A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma Phase 2
Not yet recruiting NCT06068881 - A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation Phase 2
Active, not recruiting NCT04034056 - Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)